Journal
TETRAHEDRON LETTERS
Volume 88, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.tetlet.2021.153590
Keywords
Remdesivir; Nucleotide; Nucleoside; COVID-19; RdRp
Categories
Funding
- University Grants Commission (UGC), New Delhi
- CSIR, New Delhi
- Science and Engineering Research Board (SERB), Government of India [SB/S2/JCB-002/2015]
- Council of Scientific and Industrial Research (CSIR), Ministry of Science and Technology, Government of India [HCP 0029]
Ask authors/readers for more resources
Remdesivir, the first drug approved by the FDA to treat COVID-19, is highly demanded for patients infected with the SARS-CoV-2 virus. A facile approach minimizing protecting group manipulations to afford remdesivir in good overall yield is reported in this study.
Remdesivir, the first drug approved by the FDA to treat COVID-19, is in high demand for patients infected with the SARS-CoV-2 virus. Herein, we report a facile approach minimizing the protecting group manipulations to afford remdesivir in good overall yield. (c) 2021 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
